Celyad Oncology SA (EBR:CYAD)

Market Cap	16.57M
Revenue (ttm)	186.00K
Net Income (ttm)	-5.82M
Shares Out	41.43M
EPS (ttm)	-0.14
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,714
Average Volume	18,401
Open	0.4200
Previous Close	0.4300
Day's Range	0.4000 - 0.4290
52-Week Range	0.2120 - 1.2200
Beta	1.07
RSI	34.43
Earnings Date	Sep 25, 2025

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-cells. It has licensing agreement with Novartis International AG regarding the United States patents related to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 19
• Stock Exchange: Euronext Brussels
• Ticker Symbol: CYAD

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.